First Trust Direct Indexing L.P. Decreases Position in Grifols, S.A. (NASDAQ:GRFS)

First Trust Direct Indexing L.P. decreased its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 16.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 10,307 shares of the biotechnology company’s stock after selling 2,018 shares during the period. First Trust Direct Indexing L.P.’s holdings in Grifols were worth $92,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,135 shares during the last quarter. NBC Securities Inc. lifted its holdings in shares of Grifols by 2.8% during the third quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 1,433 shares in the last quarter. Signaturefd LLC boosted its position in shares of Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,153 shares during the last quarter. Creative Planning increased its holdings in Grifols by 26.4% in the 3rd quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after buying an additional 3,614 shares in the last quarter. Finally, Bank of Montreal Can raised its position in Grifols by 12.4% in the 2nd quarter. Bank of Montreal Can now owns 70,640 shares of the biotechnology company’s stock worth $446,000 after buying an additional 7,786 shares during the last quarter.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Stock Down 2.6 %

Shares of GRFS opened at $9.05 on Thursday. The firm has a fifty day simple moving average of $8.83 and a two-hundred day simple moving average of $7.84. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.